Jing L. Marantz joined Scholar Rock November 2022 as Chief Medical Officer, overseeing development and medical affairs. She has over 20 years of experience in the biopharmaceutical industry spanning R&D, business development, and commercial strategy in multiple specialties and rare diseases. Jing currently serves on the board of Arcturus Therapeutics (NASDAQ: ARCT). She was recently EVP and Chief Business Officer of Krystal Biotech, after serving on its board for a year. Prior to Krystal, Jing was Senior Vice President of Medical Affairs at Acceleron Pharma until its acquisition by Merck & Co., Inc. Jing has held leadership positions at Alnylam, Alexion, Biogen, ARIAD, and Millennium Pharmaceuticals across development, medical affairs, and business development. She was a management consultant with Strategic Decisions Group and briefly affiliated with Massachusetts General Hospital following a post-doctoral fellowship at the Dana-Farber Cancer Institute. She received her medical training from Tongji Medical College, a PhD in Biochemistry and Molecular Biology from Medical University of South Carolina, and an MBA from the University of California at Berkeley.